Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: May 25, 2010


Amit Meller, an associate professor of biomedical engineering and physics at BU, is a founder of NobleGen Biosciences, a new startup that aims to commercialize nanopore sequencing technology he developed (see article, this issue). His co-founders are Ory Zik, a serial entrepreneur, and Zeev Pearl, an intellectual property lawyer.

Frank Feist is the founding CEO of NobleGen. Most recently, he headed the commercial team of Advalytix, which was acquired by Olympus in 2005 and became part of Beckman Coulter Genomics last year. He holds an MBA from the MIT Sloan School of Management and an MS in electrical and computer engineering from the University of Massachusetts, Amherst.

Phil Buzby recently joined NobleGen as vice president of biochemistry. Until 2008, he was a senior director of intellectual property at Helicos BioSciences, and before that, a senior director of nucleic acid chemistry at Helicos. He holds a PhD in biochemistry from Washington Sate University and a BS in biochemistry and biology from Iowa State University.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.